Unified Cellular and Molecular Core
统一的细胞和分子核心
基本信息
- 批准号:7189528
- 负责人:
- 金额:$ 16.14万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-05-01 至 2012-04-30
- 项目状态:已结题
- 来源:
- 关键词:American Type Culture CollectionAntibodiesArea AnalysesArteriesBiological AssayBirdsBlood VesselsBlood capillariesCell SeparationCellsCollaborationsDataEffector CellEndothelial CellsEvaluationFreezingFundingGreen Fluorescent ProteinsHalf-LifeHumanHuman ResourcesImageIn VitroMethodsMolecularPolymerase Chain ReactionProductivityProgram Research Project GrantsProteinsRNA analysisReaderReagentResearch PersonnelReverse Transcriptase Polymerase Chain ReactionRoleSCID MiceSmall Interfering RNASourceStem cellsStimulation of Cell ProliferationSupervisionSystemTechnical ExpertiseTimeTubeUmbilical veinangiogenesisbasecapillarycell preparationcell typedata acquisitionhuman embryonic stem cellimmortalized cellimprovedmigrationprogramsquality assurancetrophoblast
项目摘要
All of the projects described in this Program Project Grant either require a constant and consistent supply of
uterine artery endothelial cells (UAEC) (Projects I and II) or use human umbilical vein endothelial cells
(HUVEC-C; immortalized cells from ATCC) as positive control for identifying human ES derived-endothelial
cells and angiogenesis bioassays (Project III)or as effector cells for trophoblast differentiation (Project IV).
The role of the core is to not only relieve the project personnel of the burden of preparing frozen stocks of
these cells, but also to provide a high quality of cell preparation and to provide uniformity of data acquisition
between the projects. Core C will also undertake to supervise technically difficult areas of analysis In
collaboration with Project 1 the core will focus on optimization of siRNA delivery systems and in collaboration
with Core B (Stem Cell Core), Core C will also advise immunohistochemical studies for evaluating integration
of human ES derived-endothelial cells into local blood vessels in SCID mice as proposed in Project III. Thus
our specific aims are to: Aim 1: Prepare, isolate, characterize, maintain and distribute UAEC frozen stocks
for Projects I and II, and also for Projects III and IV when need arises. Aim 2: Maintain and distribute
HUVEC-C as required mainly for Projects III and IV but also Projects I and II when the need arises. Aim 3:
Supervise in vitro angiogenesis assays including mitogenesis, migration, capillary tube formation assays in
Project III using human ES cell-derived endothelial cells, HUVEC or UAEC. Aim 4: Advise and supervise real
time detecting NO using fluorescent plate reader and imaging of NO and Ca2+ in cells for Projects I, II, and
, and also for Project IV when the need arises. Aim 5: Develop/optimize methods for more efficient delivery
of siRNA to UAEC and further combine with FACS (sorting of cells) purification based on green fluorescent
protein (GFP) co-delivery to transfected cells. Aim 6: Provide ongoing support for optimization of antibody
based and quantitative methods for protein and RNA analysis, including RT-PCR and siRNA as provided
during the prior funding period. Aim 7: Provide an available source of fresh reagents which have short half
life or are significantly more economical when purchased in bulk. In summary, by acting as a Core, we will
provide much needed technical expertise, essential cell supplies and quality assurance, so contributing to
the ability to directly compare data from different projects and between cell types.
本计划项目补助金中描述的所有项目都需要持续不断地提供
子宫动脉内皮细胞(UAEC)(项目I和II)或使用人脐静脉内皮细胞
(HUVEC-C;来自ATCC的永生化细胞)作为阳性对照,用于鉴定人ES衍生的内皮细胞
细胞和血管生成生物测定(项目III)或作为滋养层分化的效应细胞(项目IV)。
其核心作用是不仅减轻项目人员准备冻结库存的负担,
这些细胞,而且提供高质量的细胞制备和提供数据采集的均匀性
项目之间。核心C还将负责监督技术上困难的分析领域,
与项目1合作,核心将专注于siRNA递送系统的优化,
与核心B(干细胞核心),核心C也将建议免疫组织化学研究,以评估整合
将人ES衍生的内皮细胞移植到SCID小鼠的局部血管中。因此
我们的具体目标是:目标1:准备、分离、鉴定、维持和分发UAEC冷冻库存
项目I和II,以及项目III和IV(如有需要)。目标2:维护和分发
HUVEC-C主要用于项目III和IV,但在需要时也用于项目I和II。目标三:
监督体外血管生成试验,包括有丝分裂,迁移,毛细管形成试验,
项目III使用人ES细胞衍生的内皮细胞,HUVEC或UAEC。目标4:建议和监督真实的
对于项目I、II,使用荧光板读数器检测NO的时间和细胞中NO和Ca 2+的成像,以及
,并在有需要时为项目IV提供服务。目标5:制定/优化更有效的交付方法
并进一步与基于绿色荧光的FACS(细胞分选)纯化联合收割机结合,
蛋白质(GFP)共递送至转染的细胞。目标6:为抗体优化提供持续支持
用于蛋白质和RNA分析的基础和定量方法,包括提供的RT-PCR和siRNA
在上一个融资期。目标7:提供一个可用的新鲜试剂来源,
使用寿命长,或者批量购买时更经济。总之,作为核心,我们将
提供急需的技术专长、基本电池供应和质量保证,
能够直接比较来自不同项目和不同细胞类型的数据。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JING ZHENG其他文献
JING ZHENG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JING ZHENG', 18)}}的其他基金
Human Embryonic Stem Cell-Derived Endothelial Cells
人胚胎干细胞衍生的内皮细胞
- 批准号:
7189524 - 财政年份:2007
- 资助金额:
$ 16.14万 - 项目类别:
Human Embryonic Stem Cell-Derived Endothelial Cells
人胚胎干细胞衍生的内皮细胞
- 批准号:
8090331 - 财政年份:2001
- 资助金额:
$ 16.14万 - 项目类别:
Human Embryonic Stem Cell-Derived Endothelial Cells
人胚胎干细胞衍生的内皮细胞
- 批准号:
8300021 - 财政年份:2001
- 资助金额:
$ 16.14万 - 项目类别:
Human Embryonic Stem Cell-Derived Endothelial Cells
人胚胎干细胞衍生的内皮细胞
- 批准号:
7845661 - 财政年份:2001
- 资助金额:
$ 16.14万 - 项目类别:
Human Embryonic Stem Cell-Derived Endothelial Cells
人胚胎干细胞衍生的内皮细胞
- 批准号:
7633375 - 财政年份:2001
- 资助金额:
$ 16.14万 - 项目类别:
EFFECTS OF NITRIC OXIDE ON FETOPLACENTAL ANGIOGENESIS
一氧化氮对胎儿胎盘血管生成的影响
- 批准号:
6390690 - 财政年份:2000
- 资助金额:
$ 16.14万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 16.14万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 16.14万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 16.14万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 16.14万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 16.14万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 16.14万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 16.14万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 16.14万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 16.14万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 16.14万 - 项目类别: